Preskoči na sadržaj

BiotechShowcase & DigiMed Showcase 2020, Day 2

15. siječnja 2020.
Recap of our Day 2 activities.

Full room at our lunch panel which will beginning shortly. Follow us here for live coverage as we explore the impact of pricing, policy & payers on the healthcare environment.

2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

Michelle Keefe, President Commercial Solutions kicks off a panel of leaders @ the forefront of managing the challenges and opportunities presented by the ever-shifting landscape, including , , & @EloxxPharmaceuticals

3 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

The group begins by tackling the need for an insights-driven approach to tackling the current challenges in

2 proslijeđena tweeta 1 korisnik označava da mu se sviđa

There has been so much work to communicate the value of drugs. What more can we do? "Talk in terms that people can understand – improving quality of life, etc. – because @ the end of the day that’s what people care about."Sabrina Martucci Johnson

2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

What can do to close the gap between policymakers, and drug developers - "Advocacy is one of the gaps and it falls to all of us to close the gap." Dennis Purcell,

2 proslijeđena tweeta 1 korisnik označava da mu se sviđa

In the current environment, what resources do we have to plan for access?

2 proslijeđena tweeta 1 korisnik označava da mu se sviđa

On gaining investments: In women's health, we've had to think creatively on how can we get investment: 1) How to accelerate innovation. 2) Creative ways to address market access & time to market." Sabrina,

2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

Hot topic: What role do play in addressing market access. "Why do the PBMs get off the hook. They are the ones that get the rebates. This goes back to messaging. We need to do a better job." Dennis Purcell,

1 reply 2 proslijeđena tweeta 3 korisnika označavaju da im se sviđa

"It's surprising how much we are dependent on the healthcare machine that we don’t have a ton of influence or control over unless you are large pharma who can bundle costs. It completely impacts how people access your drugs." Sandra

2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

Enjoying this conversation on ? Download our new survey of US and EU payers and their perspectives on and :

1 reply 3 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

Thank you to our panelists from , , & for a great dialogue on & . Join us at our next panel on at 3pm Pacific @ .

4 proslijeđena tweeta 1 korisnik označava da mu se sviđa

Michelle Keefe talks with about customer demand for introducing commercial know-how far earlier in the process. At Syneos Health we shift these solutions “to the left” to help our customer secure funding, approval and most importantly access. – mjesto: Hilton San Francisco Union Square

3 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

⏱15 minute countdown: attendees, pop over to Parc 55 to join us for a session on and navigating the reimbursement landscape.

2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa

Aaron Davis from Syneos Health Consulting will lead the conversation. Learn more about Aaron, Managing Director, Value, Access and HEOR & our Consulting team here:

2 proslijeđena tweeta 1 korisnik označava da mu se sviđa

panel starts by hitting on the key findings from @ the Crossroads report. Download here: .

3 proslijeđena tweeta 1 korisnik označava da mu se sviđa

To better understand the and coverage hurdles facing , we surveyed 35 U.S. payers. Read the executive summary about our findings and ask us more at

3 proslijeđena tweeta 1 korisnik označava da mu se sviđa
3 proslijeđena tweeta

Thanks to everyone who joined us for the event. See you all on day #3.

2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa